GHK-Cu
High EvidenceA naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.
What It Is
GHK-Cu is a tripeptide-copper complex naturally found in human plasma, saliva, and urine. Its levels decline with age. Research has explored its role in stimulating collagen synthesis, promoting wound healing, and modulating gene expression related to tissue remodeling. It is one of the more extensively studied peptides in dermatology. In 2026, GHK-Cu has seen explosive search interest growth (+1,016%) driven by viral skincare content and growing consumer interest in copper peptides for hair regrowth and wound healing, making it one of the fastest-growing peptide search categories. A 2024 randomized controlled trial (n=60, women ages 40–65) applying 0.1% GHK-Cu cream for 12 weeks demonstrated 31% wrinkle reduction, 28% improved skin elasticity, and 15.6% increased collagen density versus placebo. A subsequent 2025 meta-analysis of 7 RCTs (n=456) confirmed statistically significant wrinkle reduction. A separate 12-week clinical study on 41 women with photoaged eye-area skin found GHK-Cu eye cream outperformed both placebo and vitamin K cream for reducing periorbital lines and improving skin density. A clinical trial of 21 women showed a 28% average increase in collagen after 3 months of daily application, with the top quartile achieving 51% increase — research confirmed this was mediated through epigenetic mechanisms activating skin collagen density pathways. A pilot study of 16 patients with distal inflammatory bowel disease reported a mean 60% reduction in disease severity after 12 weeks of rectal GHK-Cu treatment, expanding potential applications beyond dermatology. A 2025 Frontiers in Pharmacology study demonstrated beneficial effects of GHK-Cu on experimental colitis with documented anti-inflammatory and tissue-repair mechanisms. GHK-Cu influences expression of over 4,000 human genes — approximately 6% of the genome — shifting aged cell gene expression patterns back toward profiles characteristic of younger tissue. A 2026 review in Systems Microbiology and Biomanufacturing (Springer Nature) mapped GHK-Cu's evolution from a dermatological bioactive ingredient to a model system linking coordination chemistry, peptide bioactivity, and biomanufacturing engineering, with key advances in tandem-repeat expression, high-cell-density fermentation, and Cu(II) complex stabilization enabling scalable production. As of May 2026, GHK-Cu remains classified as a cosmetic ingredient rather than an FDA-approved drug.
Regulatory Status
GHK-Cu for non-injectable routes of administration remains Category 1 compounding eligible. On May 5, 2026, the original nominator clarified its Category 2 withdrawal applied only to injectable administration — non-injectable routes (topical, transdermal) were retained on Category 1. Injectable GHK-Cu will be reviewed by the PCAC before February 2027 for potential 503A Bulks List inclusion. GHK-Cu search interest grew +1,016% year-over-year in 2026, driven by viral skincare content and copper peptide interest in hair regrowth.
Effective: May 2026
View FDA SourceEvidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human RCT | 12-week topical 0.1% GHK-Cu cream (n=60, ages 40–65) | 31% wrinkle reduction, 28% improved elasticity, 15.6% increased collagen density vs placebo | Source |
| Human clinical (2026) | 12-week GHK-Cu eye cream in photoaged periorbital skin (n=41) | Outperformed placebo and vitamin K cream for reducing periorbital lines and improving skin density | Source |
| Clinical review (2026) | Wound healing applications — multiple wound types | Healing time reductions of 30–50% documented; used as active ingredient in FDA-cleared wound healing devices | Source |
| Review (2026) | Tripeptides in wound healing and skin regeneration — comprehensive review | GHK-Cu confirmed to stimulate fibroblast proliferation, collagen synthesis, angiogenesis, and ECM remodeling across multiple models | Source |
| Human pilot (IBD) | 16 patients with distal inflammatory bowel disease — 12-week rectal GHK-Cu | Mean 60% reduction in disease severity after 12 weeks of rectal GHK-Cu treatment | Source |
| Human clinical (collagen density) | 21 women volunteers — 3-month daily topical application | 28% average increase in collagen density; top quartile achieved 51% increase; epigenetic mechanisms activating collagen pathways confirmed | Source |
| Animal (2025) | Colitis model — GHK-Cu therapeutic effects and mechanisms | Beneficial effects on experimental colitis; anti-inflammatory and tissue-repair mechanisms documented | Source |
Commonly Discussed Benefits
Safety & Cautions
- Topical use generally well-tolerated
- Injectable GHK-Cu removed from Category 2 but awaiting PCAC review before February 2027 — non-injectable routes remain Category 1
- Systemic use less studied
- Quality varies between commercial sources
- Consult a dermatologist for skin concerns
Comparisons
See how GHK-Cu compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Pickart L. et al. — GHK peptide as a natural modulator of multiple cellular pathways. Biomed Res Int. 2015 PubMed
- [2] Pickart L. — The human tripeptide GHK-Cu in remodeling and regeneration. J Biomater Sci. 2008 PubMed
- [3] GHK-Cu as a multifunctional copper peptide: synthesis routes, process engineering and emerging applications — Systems Microbiology and Biomanufacturing, Springer Nature 2026 PubMed
- [4] Exploring the beneficial effects of GHK-Cu on an experimental model of colitis — Frontiers in Pharmacology 2025 PubMed
- [5] Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial — EurekAlert PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
BPC-157
Medium EvidenceA pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.
Epithalon
Low EvidenceA tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.
KPV
Medium EvidenceA tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.
FOXO4-DRI
Low EvidenceA senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction.